HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Dr. Cobleigh on Antibody-Drug Conjugates in Development in HER2+ Breast Cancer

April 4th 2019

Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.

[Fam]-Trastuzumab Deruxtecan Accelerates Through HER2+ Breast Cancer Pipeline

March 29th 2019

An accelerated filing of a biologics license application is planned for [fam-] trastuzumab deruxtecan (DS-8201) as a treatment for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine.

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

March 26th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

HER2+ Breast Cancer Paradigm Slated to Expand With Novel Therapies

March 26th 2019

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer

March 22nd 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Hurvitz Highlights Emerging Agents for Heavily Pretreated HER2+ Breast Cancer

March 21st 2019

Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.

Dr. Malamud on Key Data From KATHERINE Study in HER2+ Breast Cancer

March 20th 2019

Stephen C. Malamud, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses key data from the KATHERINE study in the treatment of patients with HER2-positive breast cancer.

Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer

March 14th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive breast cancer.

Dr. Chien on Tucatinib in HER2+ Breast Cancer

March 12th 2019

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

Novel Agents May Change Paradigm for Advanced HER2+ Breast Cancer

March 11th 2019

The treatment of patients with advanced HER2-positive breast cancer could be reshaped in the next several years as clinical trials of several exciting new drugs begin to yield results.

Dr. Hurvitz on FDA Approval of Subcutaneous Trastuzumab Formulation in HER2+ Breast Cancer

March 9th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the recent FDA approval of subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in the HER2-positive breast cancer space.

Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

March 8th 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab and nab-paclitaxel as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer

March 2nd 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the optimal duration of trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Novel Agents, Approaches Drive Progress in HER2+ Breast Cancer

March 2nd 2019

Erika P. Hamilton, MD, shares insight on the management of patients with HER2-positive breast cancer and strategies aimed at targeting treatment resistance and toxicity.

FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer

February 28th 2019

The FDA has approved subcutaneous use of trastuzumab and hyaluronidase-oysk injection in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, in combination with paclitaxel in patients with metastatic HER2-positive breast cancer as a frontline treatment, and alone for patients with metastatic disease who have received at least 1 prior chemotherapy regimen

Dr. Shao on Prognosis of Patients With HER2+ Breast Cancer

February 22nd 2019

Theresa Shao, MD, assistant professor of hematology-oncology, Icahn School of Medicine, Tisch Cancer Institute, Mount Sinai Health System, discusses the prognosis of patients with HER2-positive breast cancer.

Options Shift Paradigm of Locally Advanced HER2+ Breast Cancer

February 18th 2019

Theresa Shao, MD, discusses the neoadjuvant and adjuvant findings with pertuzumab as well as the adjuvant use of neratinib in patients with locally advanced HER2-positive breast cancer.

Dr. Hamilton on Emerging Therapies in HER2+ Breast Cancer

February 12th 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses emerging therapies in HER2-positive breast cancer.

HER2+ Breast Cancer Treatment Evolving With New Data, Novel Agents

February 7th 2019

Erika P. Hamilton, MD, reflects on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.

Margetuximab Improves PFS in Metastatic HER2+ Breast Cancer

February 7th 2019

Margetuximab in combination with chemotherapy improved progression-free survival compared with trastuzumab and chemotherapy in heavily pretreated patients with metastatic HER2-positive breast cancer.